CT texture analysis for prediction of EGFR mutational status and ALK rearrangement in patients with non-small cell lung cancer.
Adult
Aged
Aged, 80 and over
Anaplastic Lymphoma Kinase
/ genetics
Carcinoma, Non-Small-Cell Lung
/ diagnosis
DNA Mutational Analysis
DNA, Neoplasm
/ genetics
ErbB Receptors
/ genetics
Female
Humans
Lung Neoplasms
/ diagnosis
Male
Middle Aged
Mutation
Predictive Value of Tests
Retrospective Studies
Tomography, X-Ray Computed
/ methods
Anaplastic lymphoma kinase
Computed tomography
Epidermal growth factor
Non-small cell lung cancer
Radiomics
Texture analysis
Journal
La Radiologia medica
ISSN: 1826-6983
Titre abrégé: Radiol Med
Pays: Italy
ID NLM: 0177625
Informations de publication
Date de publication:
Jun 2021
Jun 2021
Historique:
received:
06
04
2020
accepted:
03
12
2020
pubmed:
30
1
2021
medline:
1
6
2021
entrez:
29
1
2021
Statut:
ppublish
Résumé
To develop a CT texture-based model able to predict epidermal growth factor receptor (EGFR)-mutated, anaplastic lymphoma kinase (ALK)-rearranged lung adenocarcinomas and distinguish them from wild-type tumors on pre-treatment CT scans. Texture analysis was performed using proprietary software TexRAD (TexRAD Ltd, Cambridge, UK) on pre-treatment contrast-enhanced CT scans of 84 patients with metastatic primary lung adenocarcinoma. Textural features were quantified using the filtration-histogram approach with different spatial scale filters on a single 5-mm-thick central slice considered representative of the whole tumor. In order to deal with class imbalance regarding mutational status percentages in our population, the dataset was optimized using the synthetic minority over-sampling technique (SMOTE) and correlations with textural features were investigated using a generalized boosted regression model (GBM) with a nested cross-validation approach (performance averaged over 1000 resampling episodes). ALK rearrangements, EGFR mutations and wild-type tumors were observed in 19, 28 and 37 patients, respectively, in the original dataset. The balanced dataset was composed of 171 observations. Among the 29 original texture variables, 17 were employed for model building. Skewness on unfiltered images and on fine texture was the most important features. EGFR-mutated tumors showed the highest skewness while ALK-rearranged tumors had the lowest values with wild-type tumors showing intermediate values. The average accuracy of the model calculated on the independent nested validation set was 81.76% (95% CI 81.45-82.06). Texture analysis, in particular skewness values, could be promising for noninvasive characterization of lung adenocarcinoma with respect to EGFR and ALK mutations.
Identifiants
pubmed: 33512651
doi: 10.1007/s11547-020-01323-7
pii: 10.1007/s11547-020-01323-7
doi:
Substances chimiques
DNA, Neoplasm
0
ALK protein, human
EC 2.7.10.1
Anaplastic Lymphoma Kinase
EC 2.7.10.1
EGFR protein, human
EC 2.7.10.1
ErbB Receptors
EC 2.7.10.1
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
786-794Références
Fitzmaurice C, Allen C et al (2017) Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 32 cancer groups, 1990 to 2015: a systematic analysis for the global burden of disease study. JAMA Oncol 3(524):548. https://doi.org/10.1001/jamaoncol.2016.5688
doi: 10.1001/jamaoncol.2016.5688
Barlesi F, Mazieres J, Merlio J-P et al (2016) Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the french cooperative thoracic intergroup (IFCT). The Lancet 387:1415–1426. https://doi.org/10.1016/S0140-6736(16)00004-0
doi: 10.1016/S0140-6736(16)00004-0
Hanna N, Johnson D, Temin S et al (2017) Systemic therapy for stage IV non–small-cell lung cancer: American society of clinical oncology clinical practice guideline update. JCO 35:3484–3515. https://doi.org/10.1200/JCO.2017.74.6065
doi: 10.1200/JCO.2017.74.6065
Novello S, Barlesi F, Califano R et al (2016) Metastatic non-small-cell lung cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 27:v1–v27. https://doi.org/10.1093/annonc/mdw326
doi: 10.1093/annonc/mdw326
pubmed: 27664245
Rosell R, Carcereny E, Gervais R et al (2012) Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 13:239–246. https://doi.org/10.1016/S1470-2045(11)70393-X
doi: 10.1016/S1470-2045(11)70393-X
pubmed: 22285168
Kwak EL, Bang Y-J, Camidge DR et al (2010) Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 363:1693–1703. https://doi.org/10.1056/NEJMoa1006448
doi: 10.1056/NEJMoa1006448
pubmed: 20979469
pmcid: 3014291
Choi YR, An JY, Kim MK et al (2013) The diagnostic efficacy and safety of endobronchial ultrasound-guided transbronchial needle aspiration as an initial diagnostic tool. Korean J Intern Med 28:660. https://doi.org/10.3904/kjim.2013.28.6.660
doi: 10.3904/kjim.2013.28.6.660
pubmed: 24307841
pmcid: 3846991
Lian W, Ouyang Y (2017) CT-guided aspiration lung biopsy for EGFR and ALK gene mutation analysis of lung cancer. Oncology Letters 13:3415–3422. https://doi.org/10.3892/ol.2017.5921
doi: 10.3892/ol.2017.5921
pubmed: 28521447
pmcid: 5431172
(2018) Clinical implications of transbronchial biopsy for surgically-resected non-small cell lung cancer. In Vivo https://doi.org/10.21873/invivo.11295
Hofman P (2017) ALK status assessment with liquid biopsies of lung cancer patients. Cancers 9:106. https://doi.org/10.3390/cancers9080106
doi: 10.3390/cancers9080106
pmcid: 5575609
Lin C-C, Huang W-L, Wei F et al (2015) Emerging platforms using liquid biopsy to detect EGFR mutations in lung cancer. Expert Rev Mol Diagn 15:1427–1440. https://doi.org/10.1586/14737159.2015.1094379
doi: 10.1586/14737159.2015.1094379
pubmed: 26420338
pmcid: 4889428
Liu Y, Kim J, Balagurunathan Y et al (2016) Radiomic features are associated with EGFR mutation status in lung adenocarcinomas. Clinical Lung Cancer 17:441-448.e6. https://doi.org/10.1016/j.cllc.2016.02.001
doi: 10.1016/j.cllc.2016.02.001
pubmed: 27017476
pmcid: 5548419
Nair JKR, Saeed UA, McDougall CC et al (2020) Radiogenomic models using machine learning techniques to predict EGFR mutations in non-small cell lung cancer. Can Assoc Radiol J. https://doi.org/10.1177/0846537119899526
doi: 10.1177/0846537119899526
pubmed: 32063026
Mei D, Luo Y, Wang Y, Gong J (2018) CT texture analysis of lung adenocarcinoma: can radiomic features be surrogate biomarkers for EGFR mutation statuses. Cancer Imaging 18:52. https://doi.org/10.1186/s40644-018-0184-2
doi: 10.1186/s40644-018-0184-2
pubmed: 30547844
pmcid: 6295009
Weiss GJ, Ganeshan B, Miles KA et al (2014) Noninvasive image texture analysis differentiates K-ras mutation from pan-wildtype NSCLC and is prognostic. PLoS ONE 9:e100244. https://doi.org/10.1371/journal.pone.0100244
doi: 10.1371/journal.pone.0100244
pubmed: 24987838
pmcid: 4079229
Digumarthy SR, Padole AM, Gullo RL et al (2019) Can CT radiomic analysis in NSCLC predict histology and EGFR mutation status. Medicine 98 https://doi.org/10.1097/MD.0000000000013963
Yoon HJ, Sohn I, Cho JH, et al (2015) Decoding Tumor Phenotypes for ALK ROS1 and RET Fusions in Lung Adenocarcinoma Using a Radiomics Approach, Medicine 94: 1753 https://doi.org/10.1097/MD.0000000000001753
Martin V, Bernasconi B, Merlo E et al (2015) ALK testing in lung adenocarcinoma: technical aspects to improve FISH evaluation in daily practice. J Thorac Oncol 10:595–602. https://doi.org/10.1097/JTO.0000000000000444
doi: 10.1097/JTO.0000000000000444
pubmed: 25514802
Ravanelli M, Agazzi GM, Ganeshan B et al (2018) CT texture analysis as predictive factor in metastatic lung adenocarcinoma treated with tyrosine kinase inhibitors (TKIs). Eur J Radiol 109:130–135. https://doi.org/10.1016/j.ejrad.2018.10.016
doi: 10.1016/j.ejrad.2018.10.016
pubmed: 30527295
Miles KA, Ganeshan B, Hayball MP (2013) CT texture analysis using the filtration-histogram method: what do the measurements mean? Cancer Imaging 13:400–406. https://doi.org/10.1102/1470-7330.2013.9045
doi: 10.1102/1470-7330.2013.9045
pubmed: 24061266
pmcid: 3781643
Ng F, Kozarski R, Ganeshan B, Goh V (2013) Assessment of tumor heterogeneity by CT texture analysis: can the largest cross-sectional area be used as an alternative to whole tumor analysis? Eur J Radiol 82:342–348. https://doi.org/10.1016/j.ejrad.2012.10.023
doi: 10.1016/j.ejrad.2012.10.023
pubmed: 23194641
Shafiq-ul-Hassan M, Zhang GG, Latifi K et al (2017) Intrinsic dependencies of CT radiomic features on voxel size and number of gray levels. Med Phys 44:1050–1062. https://doi.org/10.1002/mp.12123
doi: 10.1002/mp.12123
pubmed: 28112418
Blagus R, Lusa L (2013) SMOTE for high-dimensional class-imbalanced data. BMC Bioinformatics 14:106. https://doi.org/10.1186/1471-2105-14-106
doi: 10.1186/1471-2105-14-106
pubmed: 23522326
pmcid: 3648438
Peng H, Long F, Ding C (2005) Feature selection based on mutual information: criteria of max-dependency, max-relevance, and min-redundancy. IEEE Trans Pattern Anal Mach Intell 27:1226–1238. https://doi.org/10.1109/TPAMI.2005.159
doi: 10.1109/TPAMI.2005.159
pubmed: 16119262
R Core Team (2014) R: a language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria
Lin JJ, Riely GJ, Shaw AT (2017) Targeting ALK: precision medicine takes on drug resistance. Cancer Discov 7:137–155. https://doi.org/10.1158/2159-8290.CD-16-1123
doi: 10.1158/2159-8290.CD-16-1123
pubmed: 28122866
pmcid: 5296241
Cai W, Lin D, Wu C et al (2015) Intratumoral heterogeneity of ALK-rearranged and ALK/EGFR coaltered lung adenocarcinoma. J Clin Oncol 33:3701–3709. https://doi.org/10.1200/JCO.2014.58.8293
doi: 10.1200/JCO.2014.58.8293
pubmed: 26416997
pmcid: 4770798
Zito Marino F, Marino FZ, Liguori G et al (2015) Intratumor heterogeneity of ALK-rearrangements and homogeneity of EGFR-mutations in mixed lung adenocarcinoma. PLoS ONE 10:e0139264. https://doi.org/10.1371/journal.pone.0139264
doi: 10.1371/journal.pone.0139264
pubmed: 26422230
Kobayashi Y, Mitsudomi T (2016) Not all epidermal growth factor receptor mutations in lung cancer are created equal: perspectives for individualized treatment strategy. Cancer Sci 107:1179–1186. https://doi.org/10.1111/cas.12996
doi: 10.1111/cas.12996
pubmed: 27323238
pmcid: 5021039
Nagahashi M, Sato S, Yuza K et al (2018) Common driver mutations and smoking history affect tumor mutation burden in lung adenocarcinoma. J Surg Res 230:181–185. https://doi.org/10.1016/j.jss.2018.07.007
doi: 10.1016/j.jss.2018.07.007
pubmed: 30072189